All authorized agents for medicine are hereby informed that No new registrations for following products/combination products will be accepted by NMRA,
1. Moxifloxacine + Dexamethasone
2. Doxylamine Succinate + Pyridoxime Hydrochloride
3. Mefenamic acid tablets 250 mg
4. Warfarin Sodium Tablets 10 mg
CEO
NMRA
(Date: 15 March 2021)